Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01935336|
Recruitment Status : Recruiting
First Posted : September 5, 2013
Last Update Posted : January 19, 2018
|Condition or disease||Intervention/treatment||Phase|
|Adenocarcinoma of the Lung Extensive Stage Small Cell Lung Cancer Limited Stage Small Cell Lung Cancer Recurrent Non-small Cell Lung Cancer Recurrent Small Cell Lung Cancer Stage IIIA Non-small Cell Lung Cancer Stage IIIB Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer||Drug: Ponatinib||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||110 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Ponatinib in Cohorts of Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers|
|Actual Study Start Date :||May 21, 2014|
|Estimated Primary Completion Date :||November 2018|
|Estimated Study Completion Date :||November 2019|
U.S. FDA Resources
Patients receive ponatinib hydrochloride taken by mouth once or twice a day. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Ponatinib 45mg taken by mouth each day at the same time with or without food
- Prevalence of each biomarker (Part A) [ Time Frame: Up to 5 years ]Biomarker prevalence and its 95% (exact) confidence interval (CI) among the screening patients and for different histologies will be reported.
- Overlapping frequency of biomarkers (Part A) [ Time Frame: Up to 5 years ]Overlapping frequency and its 95% CI between biomarkers among the screening patients and for different histologies will also be reported.
- Objective response rate (ORR) per RECIST v1.1 (Part B) [ Time Frame: Up to 5 years ]Evaluated using Fisher's exact test with a descriptive p-value. Summarized using binomial proportions with 95% exact binomial confidence intervals.
- Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 [ Time Frame: Up to 5 years ]The number of adverse events and percentages will be tabulated per organ and per visit.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01935336
|Contact: Paula Fisk, CCRP||720-848-0676||Paula.Fisk@ucdenver.edu|
|United States, Colorado|
|University of Colorado Cancer Center||Recruiting|
|Aurora, Colorado, United States, 80045|
|Contact: Paula Fisk, CCRP 720-848-0676 Paula.Fisk@ucdenver.edu|
|Principal Investigator: Ross D Camidge, MD, PhD|
|Principal Investigator:||Ross D Camidge, MD, PhD||University of Colorado, Denver|